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ABSTRACT 
Endogenous opioid peptides mediate the effect of suckling on LH and PRL in the 
domestic pig. However, the role of opioids in modulating GH during lactation in swine 
is not known. Primiparous sows that had been immunized against GRF(1-29) conjugated 
to human serum albumin (GRF-HSA, n=5) or HSA (n=4) were used to determine 
changes in GH after naloxone. Treatments were imposed in all sows on day 21 of 
lactation when antibody titers were 9100 ± 1629. All sows received (LV.) naloxone 
(0.25 mgfkg) or saline (0.0125 mlfkg) at 15 min intervals for 165 min. Active 
immunization against GRF-HSAduring lactation decreased (P < 0.05) mean concentration 
(4.8 ± 0.2 vs 2.6 ± 0.1 ng/ml) and frequency (1.5 ± 0.3 vs 0.4 ± 0.2 peaks/4 hr). 
Concentrations of LH and PRL were similar in GRF-HSA and HSA immunized sows. 
Naloxone suppressed (P < 0.05) GH in all sows. In USA sows, naloxone abolished 
episodic release of GU and decreased average, but not basal, concentrations of GU. In 
sows immunized against GRF-HSA, naloxone decreased (P <0.05) average and basal GH 
but failed to decrease frequency of GH release. Naloxone failed to alter frequency of 
LH release. Concentrations of PRL decreased (P < 0.05) after naloxone in all sows. In 
conclusion, immunization against GRF-USA blocked most of the effect of lactation on 
GH. Blocking opioid receptors with naloxone decreased GH and PRL in all sows. In 
contrast to previous findings naloxone had no effect on LH. Opioids alter concentrations 
of GH through a GRF dependent and GRF independent pathway. 
INTRODUCTION 
During lactation, suckling by piglets causes PRL to be elevated and LH release 
to be suppressed, effects which are mediated through endogenous opioid 
peptides (1-5). Infusion or single injection of the opioid antagonist naloxone 
increased LH (2, 4, 5) and decreased PRL (2, 5). Administration of morphine 
prevented the rise in LH induced by transient removal of the litter (cessation 
of suckling, 3). Growth hormone is lactogenic in mammals, but less is known 
about control of GH during lactation in the pig. Naloxone decreased GH in 
lactating sows (6) and in rodents (7-9), but it is not clear whether this was 
due to an effect at the level of the hypothalamus or anterior pituitary. 
We investigated the site of action of opioid peptides in modulating GH 
during lactation in the pig. To accomplish this we utilized lactating sows that 
had been actively immunized against GRF [GRF(1-29)-(GlY)4-Cys-NH21 conju­
gated to human serum albumin (GRF-HSA) or HSA alone (10). This allowed 
differentiation of the effects of suckling on GH at the level of the hypothalamus, 
hypophysis or both. 
MATERIALS AND METHODS 

Crossbred gilts that had been previously immunized against GRF-HSA (n=5) 
or HSA (n=4) were used (10). Immunizations were initiated at 180 + 1 day 
of age and boosters were given at 243 + 1 and 271 + 1 day of age (10). 
Antibody titers, expressed as dilution of serum required to bind 50% of 1251_ 
GRF, averaged 32,000 + 8916 and 36,800 + 5,248 at 243 and 271 day of 
age, respectively. Primary and booster immunizations were accomplished by 
injecting pigs with 2 and 1 mg, respectively, of a GRF(I-29)-NH2 analog, 
GRF(I-29)-(GlY)4-Cys-NH2' designed to be specifically conjugated at the car­
boxyl terminus of an equal amount ofHSA (GRF-HSA) or HSAalone. Conjugation 
of the GRF analog and HSA was performed by the m-maleimido-benzoyl-N­
hydroxy-succinimide procedure (11). 
Gilts were mated to crossbred boars at first estrus detected beyond 271 ± 
1 day of age. A booster immunization of 1 mg of GRF-HSA or HSA was given 
at day 97 + 2 of gestation. Blood samples were obtained via venipuncture on 
day 109 of gestation for determination of antibody titers against GRF. 
Litter sizes were standardized within treatment during 48 hr after parturition. 
Sows and pigs were penned in individual farrowing crates throughout lactation 
and sows were fed to appetite twice daily according to NRC recommendations 
(12). Litter size on day 21 of lactation was 8.3 + 0.3 and 7.2 ± 0.6 pigs for 
HSA and GRF-HSA sows, respectively. 
Catheters were inserted into the vena cava via a jugular vein on day 19 of 
lactation. Naloxone and saline were administered on day 21 of lactation. Sows 
received (Lv.) naloxone (0.25 mg/kg/injection) or saline (0.0125 ml/kg/ 
injection) every 15 min from 0800 to 1045 or 1400 to 1645 according to a 
crossover design. Sows in replicate 1 received saline during the AM and naloxone 
during the PM (GRF-HSA, n=3; HSA, n=2), whereas sows in replicate 2 received 
naloxone during the AM and saline during the PM (GRF-HSA, n=2; HSA, n=2). 
Sows were fed 1.35 kg of a corn-soybean meal diet at 0700 and at 1300. Blood 
samples were collected at 15-min intervals from 0730 to 1200 and from 1330 
to 1800. Naloxone or saline was administered immediately after obtaining a 
blood sample. Samples were stored at 4 C for 18 hr, centrifuged at 3,000 x 
g for 30 min and serum was decanted and stored at -20 C until assayed. All 
samples were analyzed for GH and LH and samples collected at 0730, 0800, 
0930, 1030, 1130, 1330, 1400, 1530, 1630 and 1730 were analyzed for PRL. 
Antibody titers against GRF were determined as previously described (10) 
by incubating various dilutions of serum with 125I-GRF (1-29)-NH2. Dilutions 
of serum were made in 0.02 M sodium phosphate (pH=7.2; GRF buffer). 
Antibody titer was expressed as initial dilution required to bind 50% of 1:Z51_ 
GRF in GRF-HSA sows or percentage binding at a dilution of 1:100 in HSA 
sows. Non-specific binding was consistently less than 1 %. 
On day 1, diluted serum (0.4 ml assayed in duplicate), GRF buffer (0.1 ml) 
and 125I_GRF (0.1 ml, 10-12,000 cpm in GRF buffer) were aliquoted into plain 
glass tubes, mixed with a vortex and incubated for 18 to 24 hr at 4 C. Non­
specific binding was determined by incubating 0.5 ml GRF buffer with 1251_ 
GRF. On day 2, goat anti-pig gamma globulin (0.1 ml, 1:2 in GRF buffer) and 
normal pig serum (0.1 ml, 4% in GRF buffer) was added to all tubes, mixed 
with a vortex and incubated at 4 C for 10 min. Bound and free 125I-GRF were 
separated by adding 1 ml, 6% poly-ethyleneglycol in GRF buffer, incubating 
for 1 hr and centrifuging at 3000 X g for 40 min. 
Radio-labeled GRF was prepared by incubating GRF (10 ).lg in 20 J.lI 0.6 N 
ammonium acetate), 1 mCi 1:l51 and 2 J.lg iodogen (1, 3, 4, 6 - tetrachloro-3 
alpha, 6 alpha-diphenylglycouril) for 8.5 min. The reaction was stopped by 
transferring the mixture to a 30 X 0.7 cm carboxymethyl cellulose column 
preconditioned with ammonium acetate buffer (0.002 N; pH=7.2). Labeled 
GRF was eluted with increasing'concentrations of ammonium acetate (0.01 to 
0.6 	N). 
Concentrations of GH were measured by procedures previously validated 
(10) using antiserum provided by A. F. Parlow (AFP 10318545). Average intra­
and inter-assay CV's were 5.4% and 9.7%, respectively. Luteinizing hormone 
was measured as previously validated (13) with modifications (14). Intra-assay 
CV was 16.4%. Concentrations of PRL were quantified according to validated 
procedures (15). Intra-assay CV was 13.8%. 
Data for serum concentrations of LH, GH and PRL were analyzed by split­
plot analyses of variance (16) using general linear models (1 7). The full model 
utilized for GH, LH and PRL included treatment (GRF vs GRF-HSA), replicate 
(1 vs 2), treatment x replicate, sow within treatment x replicate, period 
(naloxone vs saline), period x treatment, time and two-way interactions in­
volving time. Effect of treatment, replicate and treatment x replicate were 
tested using the sow within treatment x replicate mean square as the error 
term; period and period x treatment were tested using the period x sow within 
treatment mean square as error term. Initial analyses indicated that replicate 
or the treatment x replicate interaction did not contribute (P > 0.5) to variation 
in GH; therefore, subsequent analyses did not include replicate or treatment 
x replicate. Split-plot analyses were then performed within treatment and 
within treatment and period to more clearly define the effects of naloxone and 
time, respectively, on GH. In order to more clearly ascertain temporal changes 
in GH, data were broken down into hourly periods before (-30, -15 and 0 min 
before injection; 0 hr) and after initial injection of naloxone or saline (1, 2, 
3 and 4 hr). Models as previously described were utilized with the exception 
that time was replaced by hour. Hourly means were separated using Student­
Newman Keuls test. The treatment and period x treatment effects did not 
contribute to variation in LH and PRL, thus data were pooled across treatment. 
An episode of GH or LH release was defined as values that exceeded a 
previous nadir by at least 50% and the increase had to be greater than the 
sensitivity of the assay. Basal GH was defined as the mean of all samples during 
a sampling period excluding those associated with episodic release of GH. 
Frequency of release and basal GH were analyzed by one way analyses of 
variance using a model that included treatment (GRF vs GRF-HSA), period 
(naloxone vs saline) and period x treatment. 
RESULTS 
Antibody titers against GRF on day 109 of gestation and day 21 of lactation 
were 12,000 + 2,832 and 9,100 ± 1,629, respectively. Titers ranged from 
2,000 to 16,000 in GRF-HSA gilts on day 21. Serum for HSA pigs bound <10% 
at 1:100. 
Characteristics of GH secretion in lactating sows immunized against GRF­
HSA or HSA and administered naloxone or vehicle (saline) are in Table 1. 
Average GH from -30 to 240 min from initiation of saline is in Figure 1. Active 
immunization against GRF decreased (P < 0.05) average concentrations of GH 
n 

TABLE 1. EFFECT OF NALOXONE ON AVERAGE (± SEM) CHARACTERISTICS OF SECRETION OF GH IN SOWS 

IMMUNIZED AGAlNST HSA OR GRF-HSA. 

Average GH, ng/ml Basal GH, ng/ml Frequency, peaks/4 hr 

Saline Naloxone Saline Nalaoxone Saline Naloxone 

HSA 4.8 ± D.2-·b 3.2 ± 0.1- 4.1 ± 0.2- 3.2 ± 0.1" 1.5 ± 0.3-,b O±D 

GRF-HSA 2.6 ± O.lb 2.0 ± 0.1 2.4 ± O.lb 2.0 ± 0.1 0.4 ± 0.2 o ± 0 

ap < 0.05, HSA vs GRF-HSA. 
bp < 0.05, saline vs naloxone. 
(Table 1, Figure 1), by suppressing episodic release of GH (Table 1). Im­
munization against GRF-HSA also decreased basal GH concentrations (Table 
1). 
Changes in average GH from 0 to 4 hr from naloxone or saline in GRF-HSA 
and HSA immunized sows are shown in Figure 2. Initial analysis revealed that 
treatment, period, hour and the period x hour interaction contributed (P < 
0.01) to variation in GH. The treatment x period and treatment x hour 
interactions were not significant (P > 0.10). In GRF-HSA and HSA immunized 
sows, concentrations of GH were lower (P < 0.05) at 1, 2, 3 and 4 hr than 
at 0 hr from initial injection of naloxone; however, concentrations of GH at 
hours 0, 1, 2, 3 and 4 from saline were similar in all sows (Figure 2). Episodes 
of GH release were not detected in any sow from 15 to 240 min after initiation 
of naloxone. Frequency of release of GH (Table 1) was suppressed by naloxone, 
but not saline, in HSA sows. Basal GH was not decreased (P > 0.10) by naloxone 
in HSA sows (Table 1). Frequency of GH release was not decreased (P > 0.10) 
by naloxone in GRF-HSA immunized sows; however, basal GH was decreased 
(P < 0.05) by naloxone, but not saline, in GRF-HSA immunized sows (Table 
1). 
Concentrations of PRL were not altered by immuno-neutralization of GRF 
(data not presented). Serum concentrations of PRL from -30 to 210 min from 
saline or naloxone averaged across GRF-HSA and HSA immunized gilts are 
depicted in Figure 3. Naloxone resulted in a decrease in PRL at 90, 150 and 
210 min after initiation of injections. 
Serum LH was not altered by immunization against G RF (data not shown) 
nor by administration of naloxone (Figure 4). Concentrations of LH in all sows 
were near the assay senSitivity (.2 ng/ml) and overall frequency of LH release 
averaged 0.25 ± 0.25 peaks/4 hr. 
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Fig. 1. Changes in average GH in sows immunized against GRF·HSA or HSA alone. Saline was 
administered at IS-min intervals from 0 to 165 min. Concentrations of GH were lower (P < 0.05) 
in GRF-HSA than in HSA sows. Values are the mean ± SEM of four (HSA) or five (GRF-HSA) sows. 
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Fig. 2. Effect of saline or naloxone on GH in sows immunized against HSAor GRF-HSAadministered 
saline or naloxone. Naloxone or saline was administered during hour 1, 2 and 3. Concentrations 
of GH were lower (P < 0.05) following naloxone than saline in both sows immunized against 
HSA and sows immunized against GRF. Values represent the mean + SEM of 3 (0 hr) or 4 (1, 2, 
3, 4 hr) samples per sow (HSA, n=4; GRF-HSA, n=5). 
DISCUSSION 
These data demonstrate that elevated concentrations of GH in the lactating 
pig are primarily due to an opioid modulated increase in GRF. Active immu­
nization against GRF abolished episodic secretion of GH, thereby lowering 
average blood concentration. Wehrenberg (18) demonstrated that passive im­
munization against G RF lowered basal and suckling-stimulated concentrations 
of GH in the rat. Antagonism of opioid receptors in control (HSA) sows resulted 
in a decrease in concentration and frequency of GH release, similar to values 
in saline-treated GRF-immunized sows (Figure 2). Other reports have dem­
onstrated that naloxone decreased GH in suckled rat (7-9) and pig (6). An 
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Fig. 3. Average PRL from -30 to 210 min from saline or naloxone. Concentrations of PRL were 
similar (P > 0.10) in GRF-HSA and HSA sows, thus data were pooled. Naloxone or saline was 
administered at 15-min intervals from 0 to 165 min. Serum PRL decreased following naloxone (P 
< 0.05) but not following saline. Values are the mean ± SEM of four (HSA) or five (GRF-HSA) 
sows. 
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Fig. 4. Average LH from -30 to 210 min from saline or naloxone. Concentrations of LH were 
similar (P > 0.10) in GRF·HSA and HSA sows, thus data were pooled. Naloxone or saline was 
administered at IS-min intervals from 0 to 165 min. Concentrations of LH were similar (P > 
0.10) following saline or naloxone. Values represent the mean ± SEM of four (HSA) or five (GRF­
HSA) sows. 
effect of opioids on GH during lactation is also supported by the observation 
that an opioid agonist increases GH in lactating beef cows (19). 
Although the primary role of opioids in mediating the effects of suckling on 
GH are apparently via GRF, these results demonstrate an effect on GH inde­
pendent of GRF. Antagonism of opioid receptors with naloxone in sows im­
munized against GRF resulted in a small, but significant decrease in GH (Figure 
2). In addition, naloxone decreased basal GH in gilts immunized against GRF­
HSA, but not HSA. This effect may be unique to lactation and (or) during 
suckling, because active immunization against GRF in cyclic gilts did not lower 
basal GH, while episodic release of GH was abolished (10). The exact nature 
of this non-GRF dependent effect of opioids on GH cannot be determined from 
these data. However, hypophyseal stalk transection of the pig elevates basal 
GH, due to decreased amount of somatostatin reaching the pituitary (20). 
Thus, suckling may alter GH by decreasing somatostatin and increasing GRF. 
These results corroborate our earlier report that opioids stimulate GH in 
swine (10) and ruminants (21, 22) primarily through a hypothalamic mech­
anism. Passive immunization of rats against GRF blocked the stimulatory effect 
of morphine (23), beta-endorphin (24) or FK33-824 (8, 25-27) on release of 
GH. Met-enkephalin fibers are located in close proximity to GRF cell bodies 
in the median eminence of the rat (28) and release of GH from porcine 
somatouopes in vitro was not affected by enkephalin analogs (29). 
Results from this experiment extend previous results (2, 5) that suckling 
affects PRL in sows through a mechanism that involves opioids. Others reported 
that agonists of opioids elevated PRL (30, 31). Suckling caused an increase in 
PRL and beta-endorphin in rats (32) and sheep (33). 
Failure of naloxone to increase episodic release of LH in primiparous lactating 
sows conflicts with previous results that infusion of naloxone, at concentrations 
similar to those used in this study, increased frequency of LH release (2), or 
a single injection of naloxone increased LH (4,5) in lactating multiparous 
sows. This discrepancy is likely to be related to the fact that primiparous sows 
were used in this study, whereas multiparous sows were used in previous 
studies (2, 4, 5). Intervals from weaning to estrus are typically longer and 
concentrations of LH lower in primiparous than in multiparous sows (1). 
Further studies are necessary to evaluate the role of opioids in mediating the 
effects of suckling on LH in primiparous sows. 
In summary, antagonism of opioid receptors with naloxone decreased GH 
in lactating primiparous sows immunized against GRF-HSA or HSA. A decrease 
in GH in sows with GRF immuno-neutralized indicates that a portion of the 
effects of suckling on GH are not dependent on GRF. 
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